See feature articles below: (SKLN: SFOR: NWBO: AMRN)
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Full Report (NASDAQ:SKLN)
Skyline Medical Inc (SKLN) has received overwhelmingly positive real-world cost savings and safety feedback for its flagship product, the STREAMWAY System®, from Tucson Medical Center’s (“TMC”) Radiology department, which was included in a case study issued earlier this month.
According to TMC, the STREAMWAY System allows their radiology department to lower waste fluid disposal costs per procedure by 77.6% to $24.00, an impressive decrease from the $107.10 TMC was spending on each procedure using evacuated bottles. As a result, TMC was able to report an ROI in the first nine months of utilizing the STREAMWAY System since being installed in 2015, and anticipates a cost savings for the 1 system currently installed of $22,140 annually.
Source: News Oracle
Full Report (OTCMKT: SFOR)
On4/13/2016, shares of Strikeforce Technologies Inc (OTCMKTS:SFOR) unchanged +0.0000% in trading session and finally closed at $0.0022. The company most recent volume stood at 307.36 million shares as compared to its average volume of 199.5 thousand shares. Over the one year trading period, the stock has a high price of $390.0000 and its low is recorded at $0.0018. The company has a market cap of $23236.40.
Due to negative move, the stock’s recent closing price is lower than its previous close of $0.0022.
During the last trading period, the peak price level of the share was $0.0027; it means it is top price of day and down price level of the share was $0.0018; it means minimum price of the day at which share is traded.
The share price showed down trend from its 200 days moving average of $0.1225 with -98.2038% and highlighted negative move of -61.9998% from 50 days moving average of $0.0058.
StrikeForce Technologies, Inc. operates as a software development and services company in the United States and internationally.
Source: Street Updates
Full Report (NASDAQ: NWBO)
The different research groups’ active in the market deploys their terminology for giving their Buy/Sell recommendations. Investors not accustomed with a particular broker could find the buy/sell recommendations tough to interpret. To solve this problem, Zacks lists an analyst brokerage rating on a 1 to 5 sliding scale. If the rating is one, it is stated as buy recommendation, while five is known as Strong Sell.
Brokerages maintain a strong outlook on Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) shares. Based on the Zacks poll results, as of 2016-04-17, the stock has an ABR of 1 rating. This number highlights the scoring on a 1 to 5 scale, where 1 implies Strong Buy and 5 indicates a Strong Sell. Zacks included as many as 1 sell-side firms in its poll.
Technical Analysis is the thorough study of supply and demand in the market. It is done by comparing the stock price movements and the number of shares traded. Understanding the price movement about the High, Open, Low and Closing Prices of stock on a given minute, hour, month, day, or week and comparing with volume offers an insight of future market direction.
Analysts give price targets by technical analysis. It can be defined as a projected price level by an investment analyst. An estimate that, if achieved, results in a trader knowing the best possible outcome for investments. It is the looked on the level at which the trader would book profits in existing position.
The brokerages have a one-year mean price target of $8 for Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) stock while the median stock price estimate is $8. The highest price estimate is $8 while the lowest price target is $8. The standard deviation of given estimates is 0.
Source: Realist Investor
Full Report (NASDAQ:AMRN)
Balyasny Asset Management LLC raised its position in shares of Amarin Co. plc (NASDAQ:AMRN) by 101.9% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 2,110,357 shares of the biopharmaceutical company’s stock after buying an additional 1,065,357 shares during the period. Balyasny Asset Management LLC owned approximately 1.15% of Amarin Co. plc worth $3,989,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. Clearbridge LLC boosted its stake in Amarin Co. plc by 3.9% in the fourth quarter. Clearbridge LLC now owns 2,004,747 shares of the biopharmaceutical company’s stock worth $3,789,000 after buying an additional 75,020 shares during the period. OppenheimerFunds Inc. boosted its stake in Amarin Co. plc by 0.5% in the fourth quarter. OppenheimerFunds Inc. now owns 5,323,360 shares of the biopharmaceutical company’s stock worth $10,061,000 after buying an additional 27,090 shares during the period. Tamarack Advisers LP acquired a new stake in Amarin Co. plc during the fourth quarter worth $10,395,000. Finally, Oracle Investment Management Inc. boosted its stake in Amarin Co. plc by 9.4% in the fourth quarter.
Oracle Investment Management Inc. now owns 6,645,793 shares of the biopharmaceutical company’s stock worth $12,561,000 after buying an additional 568,915 shares during the period.
Shares of Amarin Co. plc (NASDAQ:AMRN) opened at 1.74 on Thursday. Amarin Co. plc has a 12-month low of $1.24 and a 12-month high of $2.80. The stock’s 50 day moving average price is $1.54 and its 200 day moving average price is $1.73. The firm’s market capitalization is $318.99 million.
Amarin Co. plc (NASDAQ:AMRN) last issued its quarterly earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.03. During the same period in the previous year, the company posted ($0.11) earnings per share. The business had revenue of $26.40 million for the quarter, compared to analyst estimates of $23.62 million. The business’s revenue for the quarter was up 61.4% on a year-over-year basis. Equities research analysts expect that Amarin Co. plc will post ($0.38) earnings per share for the current year.
Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Amarin Co. plc in a research report on Friday, February 26th. Zacks Investment Research upgraded Amarin Co. plc from a “sell” rating to a “hold” rating in a research report on Wednesday, January 6th.
In other Amarin Co. plc news, CEO John F. Thero purchased 25,000 shares of Amarin Co. plc stock in a transaction dated Monday, February 1st. The shares were acquired at an average cost of $1.37 per share, with a total value of $34,250.00. Following the completion of the transaction, the chief executive officer now owns 661,743 shares in the company, valued at approximately $906,587.91. The transaction was disclosed in a filing with the SEC, which is available at this link.
Amarin Corporation plc (NASDAQ:AMRN) is a biopharmaceutical company. The Company is engaged in the commercialization and development of therapeutics for cardiovascular health. Amarin’s lead product, Vascepa (icosapent ethyl) capsules, are used as an adjunct to diet to reduce triglyceride levels in adult patients with severe (triglyceride or TG over 500 milligrams per deciliter) hypertriglyceridemia.
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article with exception to FNJN.
Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.